Rhythm Pharmaceuticals (RYTM) Current Deferred Revenue (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 9 years of Current Deferred Revenue data on file, last reported at $48000.0 in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $48000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $48000.0 (changed N/A YoY), and the FY2025 annual result was $194000.0, down 84.91% from the prior year.
• Current Deferred Revenue declined to $48000.0 in Q1 2026 per RYTM's latest filing, from $194000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $9.4 million in Q1 2022 and troughed at $48000.0 in Q1 2026.
• A 5-year average of $1.8 million and a median of $1.3 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue changed 0.0% in 2024, then slumped 84.91% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $1.4 million in 2022, then slipped by 10.32% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then tumbled by 84.91% to $194000.0 in 2025, then plunged by 75.26% to $48000.0 in 2026.
• Business Quant data shows RYTM's Current Deferred Revenue at $48000.0 in Q1 2026, $194000.0 in Q4 2025, and $1.3 million in Q4 2024.